Protease-activated receptor 4 (PAR4) is a G-protein coupled receptor that is expressed on
human platelets and activated by the coagulation enzyme thrombin. PAR4 plays a key role …

The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …

Hereditary angioedema (HAE) is a rare and potentially life-threatening disease that affects
an estimated 1 in 50 000 individuals worldwide. Until recently, prophylactic HAE treatment …

Antithrombotic agents that are inhibitors of factor XIa (FXIa) have the potential to
demonstrate robust efficacy with a low bleeding risk profile. Herein, we describe a series of …

Structure–activity relationship optimization of phenylalanine P1′ and P2′ regions with a
phenylimidazole core resulted in a series of potent FXIa inhibitors. Introducing 4 …

Over the past few decades, drug discovery directed at the treatment and prevention of
thromboembolic diseases has been challenged by the need to balance robust efficacy with …

An efficient palladium-catalyzed coupling between a pyrazole amide and a heteroaryl
bromide was developed to enable the streamlined synthesis of a lead candidate for …

The strain on Britain's National Health Service is plain for all to see. Serious under-
investment, under-staffing, ill-conceived part-privatisation schemes and strategic failure in …

Although blood circulation is highly regulated, dysfunctional activities resulting from either
deficient or excessive coagulation have serious health consequences. Insufficient clotting …